Bicycle Therapeutics Plc (BCYC)
6.51
+0.04
(+0.62%)
USD |
NASDAQ |
Jan 16, 16:00
6.50
-0.01
(-0.15%)
After-Hours: 20:00
Bicycle Therapeutics Enterprise Value: -190.26M for Jan. 16, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -20.03M |
| Mereo BioPharma Group Plc | 53.46M |
| Autolus Therapeutics Plc | 323.55M |
| DBV Technologies SA | 514.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -58.75M |
| Revenue (Quarterly) | 11.66M |
| Total Expenses (Quarterly) | 70.41M |
| EPS Diluted (Quarterly) | -0.8476 |
| Gross Profit Margin (Quarterly) | 85.04% |
| Profit Margin (Quarterly) | -503.7% |
| Earnings Yield | -55.71% |
| Normalized Earnings Yield | -56.40 |